{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:41:15Z","timestamp":1778884875194,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jmii.2021.05.009","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T01:48:51Z","timestamp":1625276931000},"page":"787-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis"],"prefix":"10.1016","volume":"54","author":[{"given":"Eduardo","family":"P\u00e9rez-Alba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Nuzzolo-Shihadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Mayela","family":"Aguirre-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Espinosa-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Diego","family":"Lecona-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romulo Omar","family":"Flores-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisela","family":"Mendoza-Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Camacho-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2021.05.009_bib1","author":"WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard"},{"key":"10.1016\/j.jmii.2021.05.009_bib2","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2021.05.009_bib3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jmii.2021.05.009_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in Covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jmii.2021.05.009_bib5","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jmii.2021.05.009_bib6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1016\/j.jmii.2021.05.009_bib7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial.","volume":"397","author":"Horby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2021.05.009_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105967","article-title":"Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19","volume":"55","author":"Praveen","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2021.05.009_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.jmii.2021.05.009_bib10","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"Bronte","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jmii.2021.05.009_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.jmii.2021.05.009_bib12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","article-title":"Use of baricitinib in patients with moderate to severe coronavirus disease 2019","volume":"72","author":"Titanji","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jmii.2021.05.009_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for the treatment of hospitalized adults with Covid-19. A randomized double-blind placebo-controlled trial","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jmii.2021.05.009_bib14","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe Covid-19","volume":"383","author":"Berlin","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jmii.2021.05.009_bib15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"J Am Med Assoc"},{"issue":"13","key":"10.1016\/j.jmii.2021.05.009_bib16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jmii.2021.05.009_bib17","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.jmii.2021.05.009_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jmii.2021.05.009_bib19","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2021.05.009_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jmii.2021.05.009_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.jmii.2021.05.009_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci Adv"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168411822100133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168411822100133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:26:49Z","timestamp":1761658009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S168411822100133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S168411822100133X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2021.05.009","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2021.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}